In this appendix, we present and discuss strategies and methods for reporting undesirable effects or product defects related to pharma. We present the current procedures from different perspectives, namely the company, the medical doctors, the pharmacists, as well as the patients.
Back Matter - Addendum 5. Undesirable Effects or Product Defects Reporting Procedures
A. V. Penati;
2025-01-01
Abstract
In this appendix, we present and discuss strategies and methods for reporting undesirable effects or product defects related to pharma. We present the current procedures from different perspectives, namely the company, the medical doctors, the pharmacists, as well as the patients.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Penati_Addendum 5 In-Home.pdf
accesso aperto
Descrizione: Addendum 5
:
Publisher’s version
Dimensione
686.36 kB
Formato
Adobe PDF
|
686.36 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
